News Column

12 IPOs Planned for February 3 Week

February 2, 2014

Francis Gaskins

The full IPO calendar is available at IPOpremium.com Ranked by size of IPO, largest first. (1) Real estate finance Based in New York, NY , Ladder Capital ($LADR) scheduled a $225 million IPO on the NYSE with a market capitalization of $1.7 billion at a price range midpoint of $17 for Friday, February 7, 2014 . A commercial finance company, LADR conducts its business through three major business lines: commercial mortgage lending, investments in securities secured by first mortgage loans, and investments in selected net leased and other commercial real estate assets. (2) Gypsum wallboard mfg Based in Reston, VA , Continental Building Products ($CBPX) scheduled a $225 million IPO on the NYSE with a market capitalization of $750 million at a price range midpoint of $17 for Wednesday, February 5, 2014 . According to CBPX the company is a leading, high margin manufacturer of gypsum wallboard and complementary finishing products. (3) Closed end fund Based in New York, NY , CM Finance ($CMFN) scheduled a $100 million IPO on the Nasdaq with a market capitalization of $190 million at a price range midpoint of $15 for Thursday, February 6, 2014 . CMFN is a specialty finance company that invests primarily in the debt of middle-market companies. Expects to pay a 9% dividend. (4) Biopharma Based in Newark, CA , Revance Therapeutics ($RVNC) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $253 million at a price range midpoint of $15 for Thursday, February 6, 2014 . RVNC is working on providing Botox benefits without injections, by just rubbing RVNC's product on the skin. (5) Biotech Based in Cambridge, MA , Genocea Biosciences ($GNCA) scheduled a $72 million IPO on the Nasdaq with a market capitalization of $224 million at a price range midpoint of $13 for Wednesday, February 5, 2014 . GNCA is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today. (6) Gene therapy Based in Amsterdam, Netherlands , uniQure ($QURE) scheduled a $64 million IPO on the Nasdaq with a market capitalization of $235 million at a price range midpoint of $235 for Wednesday, February 5, 2014 . QURE is a leader in the field of gene therapy and has developed the first and currently the only gene therapy product to receive regulatory approval in the European Union . (7) Biopharma Based in San Diego, CA , Auspex Pharmaceuticals ($ASPX) scheduled a $61 million IPO on the Nasdaq with a market capitalization of $231 million at a price range midpoint of $11 for Wednesday, February 5, 2014 . ASPX is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. (8) Biopharma Based in Cambridge, MA , Eleven Biotherapeutics ($EBIO) scheduled a $60 million IPO on the Nasdaq with a market capitalization of $206 million at a price range midpoint of $14 for Thursday, Feb. 6, 2014 . EBIO is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. (9) Biopharma Based in Durham, NC , Argos Therapeutics ($ARGS) scheduled a $60 million IPO on the Nasdaq with a market capitalization of $247 million at a price range midpoint of $14 for Friday, February 7, 2014 . ARGS is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. (10) Specialty pharma Based in Malvern, PA , Egalet ($EGLT) scheduled a $42 million IPO on the Nasdaq with a market capitalization of $167 million at a price range midpoint of $12 for Friday, February 7, 2014 . EGLT's lead product candidate, Egalet -001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain. (11) Pharma Based in Research Triangle Park, NC , NephroGenex ($NRX) scheduled a $40 million IPO on the Nasdaq with a market capitalization of $40 million at a price range midpoint of $13 for Friday, February 7, 2014 . NRX is a pharmaceutical company focused on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. (12) Cancer diagnostics Based in San Diego, CA , Biocept ($BIOC) scheduled a $20 million IPO on the Nasdaq with a market capitalization of $52 million at a price range midpoint of $11 for Wednesday, February 5, 2014 . BIOC is an early-stage cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Equities.com


Story Tools